Searched for
STRIDES SPECIALTIES DIVISION
Strides Arcolab gains as company acquires CNS divisions of erstwhile RanbaxyThe agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs 165 crore.- Strides Arcolab posts Q3 net profit of Rs 97.39 croreThe company had posted a net profit of Rs 3,525.24 crore for the corresponding period of the previous fiscal, Strides Arcolab said in a fil...
- Goldman Sachs sells 4.2 lakh Strides shares for Rs 36.8 croreGoldman Sachs Investments Mauritius, a shareholder of Strides Arcolab, today sold 4.2 lakh shares of the drug company for Rs 36.81 crore in...
- Strides to pay dividend of Rs 500 per share post Agila saleArcolab said it will pay a special dividend of Rs 500 per equity share following the completion of its sale of Agila Specialties division t...
- Goldman Sachs sells Strides Arcolab shares for Rs 33.4 croreGoldman Sachs Investments Mauritius today sold 3.80 lakh shares of drug major Strides Arcolab for nearly Rs 33.4 crore in open market.
- Strides Arcolab plunges over 15% on completion of Agila saleThe pharmaceutical company said it has completed sale of its Agila Specialties Division to Mylan Inc for a total consideration of up to $1....
- Strides completes $1.75 billion sale of Agila Specialties to MylanStrides Arcolab said it has completed the sale of its Agila Specialties division to Mylan Inc for a total consideration of up to $1.75 bill...
- Eli Lilly aims to be among top 20 pharma companies in India by 2020US-based pharmaceutical major Eli Lilly and Company expects to be among the top 20 drug makers in India by 2020
- Strides Q4 net down 10.55 pc at Rs 61.19 crDrug firm Strides Arcolab reported a 10.55 per cent dip in consolidated net profit to Rs 61.19 crore for the fourth quarter ended December ...
- Strides Arcolab sells drug injectible business for Rs 9000 crore to MylanThe purchase values Agila at 18.7 times December 2012 operating profit of $86 million and seven times its sales of $255 million.
- Pfizer eyes buyout of Strides Arcolab unit AgilaPfizer is among the companies weighing a purchase of the injectable-medicines unit of Indian drug supplier Strides Arcolab.
- Six stocks in focus in Thursday morning tradeIndian shares are expected to trade higher. Here is a list of six stocks that are likely to be in action in morning trade today.
- Strides Arcolab inks pact with Eli LillyEli Lilly and Company and Strides Arcolab inked a pact to increse delivery of cancer medicines in emerging markets.
- Strides Arcolab inks pact with Eli Lilly for cancer drugsAgila Specialties will manufacture the cancer medicines, and Lilly will register and market them in geographies across the emerging markets...
- Strides Arcolabs' Agila Specialties Pharma Corporation forms JV with Jamp PharmaStrides Arcolabs' injectable drug division Agila Specialties Pharma Corporation has formed a 70:30 JV with Jamp Pharma to introduce injecta...
- Strides Arcolab sold 94% stake in its subsidiary Ascent Pharma health to Watson PharmaceuticalsArcolab sold 94% stake in its subsidiary Ascent Pharmahealth to Watson Pharmaceuticals for an undisclosed amount.
- Strides Arcolab gets approval for facility, anti-bacterial injectionDrug firm Strides Arcolab today said it has received approval from the European authorities for its Bangalore-based oncology facility.
- Strides Arcolab gets USFDA nod for Bangalore unit's productDrug firm Strides Arcolab today said it has received US health regulator's approval to market a product from its new facility in Karnataka.
- Strides Arcolab FY'10 net up 11.63 pc at Rs 122.44 crThe company's India brand business achieved Rs 47 crore in sales. In Africa, the company posted sales of $ 6.09 million and added four new ...
- Strides rebrands Stride Specialties as Agila SpecialtiesDrug firm Strides Arcolab today said it has rebranded its specialities division, Strides Specialties as Agila Specialties, and that it will...
Load More
